Literature DB >> 2858372

Disposition and metabolic fate of 14C-quazepam in man.

N Zampaglione, J M Hilbert, J Ning, M Chung, R Gural, S Symchowicz.   

Abstract

The absorption, metabolism, and excretion of quazepam, a new benzodiazepine hypnotic, was investigated in six normal male volunteers after oral administration of 25 mg 14C-quazepam in solution. Quazepam was well absorbed. Plasma radioactivity peaked (324.6 ng quazepam eq/ml) 1.75 hr postdose. Unchanged quazepam reached its maximum plasma level (148 ng/ml) at 1.5 hr with an apparent absorption half-life of 0.4 hr. Major plasma metabolites of quazepam were 2-oxoquazepam (OQ), obtained by replacement of S by O,N-desalkyl-2-oxoquazepam (DOQ), and 3-hydroxy-2-oxoquazepam (HOQ) glucuronide. Both OQ and DOQ are pharmacologically active. Plasma elimination half-lives for quazepam, OQ, DOQ, and radioactivity were 39, 40, 69, and 76 hr, respectively. The respective AUC (120 hr) values were 715, 438, 3323, and 11402 hr X ng/ml. Approximately 54% of the radioactive dose was excreted in the urine (31.3%) and feces (22.7%) over a 5-day period. HOQ glucuronide was the major urinary metabolite of quazepam. Other metabolites present in the urine in relatively large amounts were glucuronides of DOQ and HDOQ.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858372

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.

Authors:  Norio Yasui-Furukori; Takenori Takahata; Tsuyoshi Kondo; Kazuo Mihara; Sunao Kaneko; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 3.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 4.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

5.  Liquid chromatographic assay and pharmacokinetics of quazepam and its metabolites following sublingual administration of quazepam.

Authors:  S K Gupta; E H Ellinwood
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

Review 6.  Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.

Authors:  S I Ankier; K L Goa
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.